SpanosKSaleptsisVAthanasoulasA. Factors associated with ulcer healing and quality of life in patients with diabetic foot ulcer. Angiology. 2017;68(3):242–250.
3.
LipskyBAAragón-SánchezJDiggleM. International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis and management foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016;32(suppl 1):45–74.
4.
GiagtzidisIKarkosCPitouliasGPapazoglouK. Matrix metalloproteinases and peripheral arterial disease. Int Angiol. 2015;34(3):195–201.
5.
GarvinPJonassonLNilssonLFalkMKristensonM. Plasma matrix metalloproteinase-9 levels predict first-time coronary heart disease: an 8-year follow-up of a community-based middle aged population. PLoS One. 2015;10(9):e0138290.
6.
ZhaoHDZhangYD. The effects of previous statin treatment on plasma matrix metalloproteinase-9 level in Chinese stroke patients undergoing thrombolysis. J Stroke Cerebrovasc Dis. 2014;23(10):2788–2793.
7.
YaoXMYeSDZaiZ. Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. J Endocrinol Invest. 2010;33(5):292–296.
